2023 World Conference on Lung Cancer (Posters)-P2.31. Missed Opportunities for Lung Cancer Personalized Medicine in a Brazilian Public Healthcare Service

P2.31. Missed Opportunities for Lung Cancer Personalized Medicine in a Brazilian Public Healthcare Service - PDF(Abstract)

Back to course

Pdf Summary

This presentation at the WCLC 2023 conference focused on the missed opportunities for personalized medicine in lung cancer treatment in a Brazilian public healthcare service. The study aimed to assess the barriers to precision oncology and identify the steps where opportunities for personalized medicine were missed.<br /><br />The researchers conducted a retrospective study and reviewed the electronic medical records of 174 patients with non-squamous non-small cell lung cancer (NSq NSCLC). They evaluated the missed opportunities at various stages of the process, including access to genomic testing, feasibility of exams, availability of test results for all biomarkers, and access to targeted therapy for actionable gene mutations.<br /><br />The results showed that for patients with early-stage NSq NSCLC, 80% of patients missed the first step of accessing genomic testing. Among patients with advanced disease, 32% were unable to undergo genomic testing due to a short life expectancy. Of the patients who had access to testing, 9% had insufficient samples for analysis. Only one patient underwent testing for all recommended biomarkers, resulting in 98% of patients missing out on comprehensive testing.<br /><br />In terms of targeted therapy, 40% of the patients with actionable gene mutations did not receive targeted therapy. Among patients with EGFR-mutated tumors, only 8% were missed due to the lack of access to anti-EGFR therapy.<br /><br />The study highlights the challenges and missed opportunities in implementing precision oncology in lung cancer management, particularly in resource-limited settings. It emphasizes the need to improve access to genomic testing, ensure adequate samples for analysis, and expand the testing panel for recommended biomarkers. The researchers also identified barriers to the adoption of targeted therapy beyond EGFR mutations. These findings underscore the importance of addressing these barriers to ensure equitable access to personalized medicine in lung cancer treatment.

Asset Subtitle

Pedro Aguiar Jr

Meta Tag

Speaker Pedro Aguiar Jr

Topic Global Health, Health Services & Health Economics: Real World Data

Keywords

precision oncology

lung cancer treatment

genomic testing

barriers

missed opportunities

targeted therapy

gene mutations

comprehensive testing

resource-limited settings

equitable access